Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label attachment file name title
tabling member	label

Search

1138387

registered interest
date	11/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Carers
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the NHS Long Term Plan implementation framework, how many people have carer passports; and what targets have been set to increase the adoption of those passports.
tabling member constituency	Worsley and Eccles South
tabling member printed	Barbara Keeley
uin	276173
answer	answer is ministerial correction date of answer 16/07/2019 answer text <p>Section 2.33 of NHS England’s Long Term Plan states:</p><p>“We will continue to identify and support carers, particularly those from vulnerable communities. Carers are twice as likely to suffer from poor health compared to the general population, primarily due to a lack of information and support, finance concerns, stress and social isolation. Quality marks for carer-friendly GP practices, developed with the Care Quality Commission (CQC), will help carers identify GP services that can accommodate their needs. We will encourage the national adoption of carer's passports, which identify someone as a carer and enable staff to involve them in a patient’s care, and set out guidelines for their use based on trials in Manchester and Bristol. These will be complemented by developments to electronic health records that allow people to share their caring status with healthcare professionals wherever they present.”</p><p> </p><p>There is currently no data on the number of Carer Passports nationally and the use of theses passports is variable across the country and across different health, care and community settings.</p><p> </p><p>Work commissioned by the Department and carried out by Carers UK and Carers Trust, led to the development of a carer passport resource. The Carer Passport resource is available at the following link:</p><p><a href="https://carerspassports.uk/" target="_blank">https://carerspassports.uk/</a></p><p>This provides information on existing passport frameworks and support for the development of carer passports across a range of settings. As part of NHS England’s commitments, we will be supporting the use of these passports and promoting this through the implementation of our Quality Markers in Primary Care (launched in June), ongoing development work with sustainability and transformation partnership and integrated care system localities and as an extension of work already in progress following the response to John’s Campaign within secondary care settings. More information about John’s Campaign is available at the following link:</p><p><a href="https://johnscampaign.org.uk/#/" target="_blank">https://johnscampaign.org.uk/#/</a></p><p> </p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 16/07/2019 16:25:50 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	1588 label Biography information for Barbara Keeley

1138388

registered interest
date	11/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Training
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the NHS Long Term Plan implementation framework system support offer, how many of the 75,000 staff to be trained on personalised care approaches will work in (a) autism and learning disability and (b) mental health services.
tabling member constituency	Worsley and Eccles South
tabling member printed	Barbara Keeley
uin	276174
answer	answer is ministerial correction date of answer 16/07/2019 answer text <p>Professionals working in autism, learning disability and mental health will have access to training on personalised care approaches. The exact number to be trained will be determined locally based on staffing levels and local needs.</p><p>The Care Act 2014 places responsibilities on local authorities in England to promote their local care markets. They are required to promote a diverse, sustainable, high quality market of care and support providers for people in their local area.</p><p>Local authorities are expected to understand and articulate likely future demand for services in their area; engage with care providers to understand the likely supply of services; provide signals to the market of their intent; and as needed, intervene in the market to stimulate change and innovation in providers to better meet the needs of people and communities.</p> answering member constituency Gosport answering member printed Caroline Dinenage grouped question UIN 276177 question first answered 16/07/2019 16:23:54 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	1588 label Biography information for Barbara Keeley

1138389

registered interest
date	11/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Social Services: Staff
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the NHS Long Term Plan implementation framework system support offer, whether the Institute for Personalised Care will deliver support to staff working in social care.
tabling member constituency	Worsley and Eccles South
tabling member printed	Barbara Keeley
uin	276175
answer	answer is ministerial correction date of answer 16/07/2019 answer text <p>The Institute for Personalised Care will be in place in early September and their role is to develop products to support the quality assurance of training for clinical staff in personalised care. The products they will be responsible for include developing preferred provider frameworks and accreditation for health coaching and other elements of personalised care which is included in the current specification.</p><p>The Institute will not be delivering support to staff working in social care, but is able to provide support to staff working in integrated services.</p><p> </p><p><strong> </strong></p><p><strong> </strong></p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 16/07/2019 16:27:36 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	1588 label Biography information for Barbara Keeley

1138390

registered interest
date	11/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Social Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the NHS Long Term Plan implementation framework system support offer, what criteria will be used to determine which areas receive transformation funding to develop, test and deliver new approaches to care.
tabling member constituency	Worsley and Eccles South
tabling member printed	Barbara Keeley
uin	276176
answer	answer is ministerial correction date of answer 16/07/2019 answer text <p>It is for NHS England and NHS Improvement national and regional teams to determine jointly the allocation approach, criteria and process for the distribution of transformation funding to develop their five-year strategic plans.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 16/07/2019 12:07:17 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	1588 label Biography information for Barbara Keeley

1136415

registered interest
date	02/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Vitamins
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what assessment they have made of (1) the safety, and (2) the effectiveness, of using IV vitamin drips and other related therapies offered by retail clinics.
tabling member printed	Lord Birt
uin	HL16865
answer	answer is ministerial correction date of answer 10/07/2019 answer text <p>If retail clinics are intending to administer vitamin drips and other related therapies intravenously for a medicinal purpose then the products and associated advertising must be in compliance with all relevant aspects of medicines legislation which includes an assessment of the safety quality and efficacy for licensed medicines.</p><p>The Medicines and Healthcare products Regulatory Agency (MHRA) is the United Kingdom body responsible for ensuring that medicines work and are acceptably safe.</p><p>Intravenous drips which are not intended for a medical purpose are not medicines and these products fall outside the MHRA’s jurisdiction.</p> answering member printed Baroness Blackwood of North Oxford question first answered 10/07/2019 15:27:10 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	2533 label Biography information for Lord Birt

1136423

registered interest
date	02/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what plans they have, if any, to extend the availability of medicinal cannabis to people with diseases that cause chronic pain.
tabling member printed	Lord Jones of Cheltenham
uin	HL16873
answer	answer is ministerial correction date of answer 10/07/2019 answer text <p>The law was changed on 1 November 2018 to allow clinicians on the General Medical Council’s Specialist Register to prescribe cannabis-based products for medicinal use (CBPM), where it is clinically appropriate and in the best interest of patients. Whilst the law allows clinicians to prescribe these products for the management of chronic pain, interim guidance jointly produced by the Royal College of Physicians and the Royal College of Radiologists, in liaison with the Faculty of Pain Medicine of the Royal College of Anaesthetists, concludes that there is not yet robust evidence for the use of CBPM in chronic pain, and their use is currently not recommended.</p><p>The National Institute for Health and Care Excellence (NICE) has been commissioned to develop updated clinical guidance on the prescribing of CBPM, including for the management of chronic pain, which will be published by October 2019. It will be based on the best available international evidence and will have been produced using NICE’s world-renowned process for identifying and assessing relevant studies and delivering such guidance. NICE is expected to consult on the draft guidance between 23 July – 20 August 2019.</p><p>An initial impact assessment <em>Rescheduling of cannabis-based products for medicinal use under the Misuse of Drugs Regulations 2001 </em>was published alongside The Misuse of Drugs (Amendments) (Cannabis and Licence Fees) (England, Wales and Scotland) Regulations 2018. A copy of this impact assessment is attached. This set out the approach that the Government proposed to take in assessing the costs and benefits of the change in the law at a population level, with regard to the rescheduling of CBPM. This framework included an analysis of cost and benefits for the use of cannabis for the management of chronic pain.</p><p>To further the evidence-base, the National Institute for Health Research has issued two calls for research in this area, and is working with the industry and researchers to ensure that the evidence is developed in a way that will inform decisions on public funding. This research will be open to all good quality proposals covering any indication, including multiple sclerosis, pain and other disorders unresponsive to existing treatments.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL16874 HL16875 question first answered 10/07/2019 15:30:08 answering member 4019 label Biography information for Baroness Blackwood of North Oxford attachment 1 file name Impact_Assessment.pdf title Impact_Assessment
tabling member	248 label Biography information for Lord Jones of Cheltenham

1136424

registered interest
date	02/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what assessment they have made of (1) the advantages, and (2) the disadvantages, of allowing medical professionals to prescribe medicinal cannabis to people suffering from chronic pain.
tabling member printed	Lord Jones of Cheltenham
uin	HL16874
answer	answer is ministerial correction date of answer 10/07/2019 answer text <p>The law was changed on 1 November 2018 to allow clinicians on the General Medical Council’s Specialist Register to prescribe cannabis-based products for medicinal use (CBPM), where it is clinically appropriate and in the best interest of patients. Whilst the law allows clinicians to prescribe these products for the management of chronic pain, interim guidance jointly produced by the Royal College of Physicians and the Royal College of Radiologists, in liaison with the Faculty of Pain Medicine of the Royal College of Anaesthetists, concludes that there is not yet robust evidence for the use of CBPM in chronic pain, and their use is currently not recommended.</p><p>The National Institute for Health and Care Excellence (NICE) has been commissioned to develop updated clinical guidance on the prescribing of CBPM, including for the management of chronic pain, which will be published by October 2019. It will be based on the best available international evidence and will have been produced using NICE’s world-renowned process for identifying and assessing relevant studies and delivering such guidance. NICE is expected to consult on the draft guidance between 23 July – 20 August 2019.</p><p>An initial impact assessment <em>Rescheduling of cannabis-based products for medicinal use under the Misuse of Drugs Regulations 2001 </em>was published alongside The Misuse of Drugs (Amendments) (Cannabis and Licence Fees) (England, Wales and Scotland) Regulations 2018. A copy of this impact assessment is attached. This set out the approach that the Government proposed to take in assessing the costs and benefits of the change in the law at a population level, with regard to the rescheduling of CBPM. This framework included an analysis of cost and benefits for the use of cannabis for the management of chronic pain.</p><p>To further the evidence-base, the National Institute for Health Research has issued two calls for research in this area, and is working with the industry and researchers to ensure that the evidence is developed in a way that will inform decisions on public funding. This research will be open to all good quality proposals covering any indication, including multiple sclerosis, pain and other disorders unresponsive to existing treatments.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL16873 HL16875 question first answered 10/07/2019 15:30:09 answering member 4019 label Biography information for Baroness Blackwood of North Oxford attachment 1 file name Impact_Assessment.pdf title Impact_Assessment
tabling member	248 label Biography information for Lord Jones of Cheltenham

1136425

registered interest
date	02/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what studies (1) have been carried out, and (2) are proposed, to investigate the pain relief impacts of medicinal cannabis on people who have multiple sclerosis.
tabling member printed	Lord Jones of Cheltenham
uin	HL16875
answer	answer is ministerial correction date of answer 10/07/2019 answer text <p>The law was changed on 1 November 2018 to allow clinicians on the General Medical Council’s Specialist Register to prescribe cannabis-based products for medicinal use (CBPM), where it is clinically appropriate and in the best interest of patients. Whilst the law allows clinicians to prescribe these products for the management of chronic pain, interim guidance jointly produced by the Royal College of Physicians and the Royal College of Radiologists, in liaison with the Faculty of Pain Medicine of the Royal College of Anaesthetists, concludes that there is not yet robust evidence for the use of CBPM in chronic pain, and their use is currently not recommended.</p><p>The National Institute for Health and Care Excellence (NICE) has been commissioned to develop updated clinical guidance on the prescribing of CBPM, including for the management of chronic pain, which will be published by October 2019. It will be based on the best available international evidence and will have been produced using NICE’s world-renowned process for identifying and assessing relevant studies and delivering such guidance. NICE is expected to consult on the draft guidance between 23 July – 20 August 2019.</p><p>An initial impact assessment <em>Rescheduling of cannabis-based products for medicinal use under the Misuse of Drugs Regulations 2001 </em>was published alongside The Misuse of Drugs (Amendments) (Cannabis and Licence Fees) (England, Wales and Scotland) Regulations 2018. A copy of this impact assessment is attached. This set out the approach that the Government proposed to take in assessing the costs and benefits of the change in the law at a population level, with regard to the rescheduling of CBPM. This framework included an analysis of cost and benefits for the use of cannabis for the management of chronic pain.</p><p>To further the evidence-base, the National Institute for Health Research has issued two calls for research in this area, and is working with the industry and researchers to ensure that the evidence is developed in a way that will inform decisions on public funding. This research will be open to all good quality proposals covering any indication, including multiple sclerosis, pain and other disorders unresponsive to existing treatments.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL16873 HL16874 question first answered 10/07/2019 15:30:09 answering member 4019 label Biography information for Baroness Blackwood of North Oxford attachment 1 file name Impact_Assessment.pdf title Impact_Assessment
tabling member	248 label Biography information for Lord Jones of Cheltenham